Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, Maria Perusini, Aniket Bankar, Marta Davidson, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Dawn Maze, Karen W.L. Yee, Mark Minden, Steven Chan, Jose-Mario Capo-Chichi, Vikas Gupta, Hassan Sibai, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2025-7051

Published: 2025

Journal Articles

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Blood (2025) 146 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2025-5183

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Factors influencing outcomes in therapy-related myeloid neoplasms following allogeneic hematopoietic stem cell transplantation

Noora Obaidallah, Sihath Singhabahu, Mats Remberger, Dennis Kim, Auro Viswabandya, Rajat Kumar, Fotios Michelis, Arjun Law, Igor Novitzky-Basso, Tommy Alfaro Moya, Eshrak Al-Shaibani, Jonas Mattsson, Ivan Pasic

Blood (2025) 146 (Supplement 1): 7823.

https://doi.org/10.1182/blood-2025-7823

Published: 2025

Journal Articles

Frailty as a prognostic factor in younger adult patients with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Sergio Rodriguez-Rodriguez, Nihar Desai, Maria Queralt Salas Gay, Eshrak Al-Shaibani, Igor Novitzky-Basso, Arjun Law, Auro Viswabandya, Fotios Michelis, Jonas Mattsson, Dennis Kim, Rajat Kumar, Tommy Alfaro Moya

Blood (2025) 146 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2025-4430

Published: 2025

Journal Articles

DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Yael Morgenstern, Oyeronke Ayansola, Jae-Sook Ahn, Maria Perusini, Flavia Patino, Danielle Pyne, Amirthagowri Ambalavanan, Hyeoung-Joon Kim, Dennis Kim

Blood (2025) 146 (Supplement 1): 7274.

https://doi.org/10.1182/blood-2025-7274

Published: 2025

Journal Articles

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Blood (2025) 146 (Supplement 1): 75.

https://doi.org/10.1182/blood-2025-75

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

Feasibility of the edmonton symptom assessment system (ESAS) score as patient-reported outcomes (PROs) assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy: A pilot Study

Maria Perusini, Noora Obaidallah, Yael Morgenstern, Flavia Patino, Dennis Kim

Blood (2025) 146 (Supplement 1): 7294.

https://doi.org/10.1182/blood-2025-7294

Published: 2025

Journal Articles

Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Reem Alasbali, Majed Altareb, Carol Chen, Tommy Alfaro Moya, Eshrak Al-Shaibani, Swe Linn, Ivan Pasic, Igor Novitzky-Basso, Arjun Law, Fotios Michelis, Auro Viswabandya, Rajat Kumar, Jonas Mattsson, Raja Prince-Eladnani, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2025-4295

Published: 2025

Journal Articles

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes

Sergio Rodriguez-Rodriguez, Nihar Desai, Brittany Salter, Amani Ahmed, Mohamed Elemary, Jonas Mattsson, Kylie Lepic, Jennifer White, Dennis Kim

Blood (2025) 146 (Supplement 1): 2470.

https://doi.org/10.1182/blood-2025-2470

Published: 2025

Journal Articles

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Sergio Rodriguez-Rodriguez, Rebeca Bailen, Keven Vachon, Brittany Salter, Christopher Lemieux, Kareem Jamani, Mohamed Elemary, Sylvie Lachance, Jonas Mattsson, Kylie Lepic, Amani Ahmed, Jennifer White, Felipe Peña-Muñoz, Juan Alberto Martín González, Jose Antonio Perez Simon, Matthias Fante, Daniel Wolff, Mi Kwon, Dennis Kim

Blood (2025) 146 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2025-4239

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Blood (2025) 146 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2025-1993

Published: 2025

Journal Articles

Immune deconvolution from whole transcriptomic data suggests expansion of exhausted T-cells and natural killer cells following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

Yael Morgenstern, Amirthagowri Ambalavanan, Jae-Sook Ahn, Maria Perusini, Flavia Patino, Danielle Pyne, Oyeronke Ayansola, Hyeoung-Joon Kim, Dennis Kim

Blood (2025) 146 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2025-1991

Published: 2025

Journal Articles

Real-world data comparison of asciminib 40 mg twice daily vs. 80 mg once daily in chronic myeloid leukemia patients

Ana Patiño, Yael Morgenstern, Noora Obaidallah, Maria Perusini, Dennis Kim

Blood (2025) 146 (Supplement 1): 7300.

https://doi.org/10.1182/blood-2025-7300

Published: 2025

Journal Articles

Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy: Proposal of long-term genomic monitoring

Yael Morgenstern, Gopila Gupta, Flavia Patino, Maria Perusini, Daniela Zackova, Ivana Jeziskova, Anezka Kvetkova, Tomas Jurcek, Azin Keshavarz, Danielle Pyne, Oyeronke Ayansola, Amirthagowri Ambalavanan, Jiri Mayer, Andrea Arruda, Mark Minden, Jessie Medeiros, Sagi Abelson, Dennis Kim

Blood (2025) 146 (Supplement 1): 3767.

https://doi.org/10.1182/blood-2025-3767

Published: 2025

Journal Articles

Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients

Blood (2025) 146 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2025-2652

Published: 2025

Journal Articles

Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis

Eshrak Al-Shaibani, Jonas Mattsson, Yu Cai, Xianmin Song, Mohsen Al Zahrani, Mohamed Elemary, Hanan Alkhaldi, Muhned Alhumaid, Ayman Saad, Francesca Biavasco, Robert Zeiser, Dennis Kim

Blood (2025) 146 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2025-4273

Published: 2025

Journal Articles

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Blood (2025) 146 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2025-4284

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Factors influencing outcomes in therapy-related myeloid neoplasms following allogeneic hematopoietic stem cell transplantation

Frailty as a prognostic factor in younger adult patients with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

DNA methylation instability as a biomarker to predict resistance or progression to advanced disease Phase following tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Feasibility of the edmonton symptom assessment system (ESAS) score as patient-reported outcomes (PROs) assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy: A pilot Study

Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes

Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival.

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Immune deconvolution from whole transcriptomic data suggests expansion of exhausted T-cells and natural killer cells following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

Real-world data comparison of asciminib 40 mg twice daily vs. 80 mg once daily in chronic myeloid leukemia patients

Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy: Proposal of long-term genomic monitoring

Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients

Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only